Is Actemra Approved for Arthritis?
Yes, Actemra (tocilizumab) is FDA-approved for treating several forms of arthritis, including moderate to severe rheumatoid arthritis (RA) in adults and children aged 2 and older who haven't responded well to TNF antagonists, polyarticular juvenile idiopathic arthritis (pJIA) in kids 2 and older, and systemic juvenile idiopathic arthritis (sJIA) in kids 2 and older.[1] It works by blocking interleukin-6 (IL-6), a protein involved in inflammation.
How Does Actemra Treat Arthritis?
Actemra reduces joint pain, swelling, and damage in RA and related conditions by targeting IL-6 signaling, which drives autoimmune inflammation. It's given as an IV infusion every 4 weeks or weekly subcutaneous injection. Clinical trials showed it improved symptoms in about 60-70% of RA patients when added to methotrexate.[1][2]
What Arthritis Types Does Actemra Cover?
Primarily RA, pJIA, and sJIA. It's not approved for osteoarthritis (wear-and-tear arthritis) or other non-inflammatory types. Off-label use for giant cell arteritis (an inflammatory condition sometimes linked to arthritis) is also approved.[1]
Who Makes Actemra and What's the Pricing?
Genentech (a Roche subsidiary) manufactures Actemra. A 4-week supply of subcutaneous injections costs $4,000-$5,000 without insurance in the US, though patient assistance programs and biosimilars may lower costs.[3]
When Does Actemra's Patent Expire?
Key US patents on Actemra expired in 2023-2025, with biosimilar competition emerging. Full exclusivity ends around 2029-2033 depending on formulations; check ongoing litigation for delays.[4]
Common Side Effects Patients Report
Infections (upper respiratory, urinary), high cholesterol, headaches, rash, and injection site reactions occur in 5-10% of users. Serious risks include liver enzyme elevation and gastrointestinal perforations—monitor closely in arthritis patients with risk factors.[1][2]
How Does Actemra Compare to Humira or Enbrel?
Actemra targets IL-6 (unlike TNF inhibitors like Humira/adalimumab or Enbrel/etanercept, which block TNF-alpha). It works for TNF failures, with similar RA response rates (ACR20 in 50-60%) but fewer injection reactions. Switch if TNF drugs fail.[2]
Sources:
[1]: FDA Label for Actemra
[2]: Arthritis Foundation on Actemra
[3]: GoodRx Pricing for Actemra
[4]: DrugPatentWatch.com - Actemra Patents